Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research.
Omics analyses
autophagy
proteotoxic stress response
replication stress
therapeutic targets
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
02
2020
accepted:
23
04
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
6
6
2020
Statut:
epublish
Résumé
While the modern therapeutic armamentarium to treat multiple myeloma (MM) patients allows a longer control of the disease, this second-most-frequent hematologic cancer is still uncurable in the vast majority of cases. Since MM plasma cells are subjected to various types of chronic cellular stress and the integrity of specific stress-coping pathways is essential to ensure MM cell survival, not surprisingly the most efficacious anti-MM therapy are those that make use of proteasome inhibitors and/or immunomodulatory drugs, which target the biochemical mechanisms of stress management. Based on this notion, the recently realized discoveries on MM pathobiology through high-throughput techniques (genomic, transcriptomic, and other "omics"), in order for them to be clinically useful, should be elaborated to identify novel vulnerabilities in this disease. This groundwork of information will likely allow the design of novel therapies against targetable molecules/pathways, in an unprecedented opportunity to change the management of MM according to the principle of "precision medicine." In this review, we will discuss some examples of therapeutically actionable molecules and pathways related to the regulation of cellular fitness and stress resistance in MM.
Identifiants
pubmed: 32500036
doi: 10.3389/fonc.2020.00802
pmc: PMC7243738
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
802Informations de copyright
Copyright © 2020 Manni, Fregnani, Barilà, Zambello, Semenzato and Piazza.
Références
FEBS J. 2019 Jan;286(2):241-278
pubmed: 30027602
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634515
Drugs R D. 2019 Jun;19(2):73-92
pubmed: 30993606
Int J Mol Sci. 2018 May 18;19(5):
pubmed: 29783691
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Blood. 2006 Sep 15;108(6):2020-8
pubmed: 16728703
PLoS One. 2013 Jul 31;8(7):e70430
pubmed: 23936203
Expert Rev Hematol. 2013 Jun;6(3):317-25
pubmed: 23782085
Leuk Res. 2017 Aug;59:97-104
pubmed: 28599191
Cancer Biol Ther. 2015;16(9):1422-6
pubmed: 26176532
Cancers (Basel). 2019 Sep 27;11(10):
pubmed: 31569720
Front Genet. 2013 Jun 11;4:109
pubmed: 23781234
Curr Opin Pharmacol. 2015 Aug;23:68-73
pubmed: 26072431
Expert Rev Anticancer Ther. 2014 Mar;14(3):251-4
pubmed: 24397833
Apoptosis. 2006 Jan;11(1):5-13
pubmed: 16374548
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Br J Haematol. 2018 Jul;182(1):11-28
pubmed: 29676460
Front Oncol. 2019 Oct 24;9:1137
pubmed: 31709194
Cancer Cell. 2013 Sep 9;24(3):289-304
pubmed: 24029229
Annu Rev Biochem. 2018 Jun 20;87:697-724
pubmed: 29652515
Leuk Res. 2016 Oct;49:7-12
pubmed: 27518808
Clin Cancer Res. 2012 Apr 1;18(7):1888-900
pubmed: 22351691
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72
pubmed: 15937109
Curr Opin Cell Biol. 2011 Apr;23(2):216-22
pubmed: 21169004
Autophagy. 2014 Aug;10(8):1380-90
pubmed: 24991834
Leukemia. 2017 Oct;31(10):2104-2113
pubmed: 28186131
Clin Cancer Res. 2004 Jun 1;10(11):3839-52
pubmed: 15173093
PLoS One. 2013 Sep 27;8(9):e75280
pubmed: 24086494
Leukemia. 2010 Oct;24(10):1804-7
pubmed: 20703255
Mol Cancer Ther. 2004 Dec;3(12):1513-24
pubmed: 15634644
Blood. 2012 Jun 14;119(24):5772-81
pubmed: 22538852
Blood. 2009 Jan 22;113(4):846-55
pubmed: 18948577
ACS Chem Biol. 2015 Nov 20;10(11):2589-97
pubmed: 26322624
Blood. 2007 May 15;109(10):4470-7
pubmed: 17255354
Cell Death Discov. 2019 May 21;5:98
pubmed: 31123604
PLoS One. 2015 Mar 13;10(3):e0119857
pubmed: 25769101
Haematologica. 2013 Jul;98(7):1132-41
pubmed: 23065523
J Clin Invest. 2015 Apr;125(4):1401-18
pubmed: 25798617
Autophagy. 2015;11(7):1161-78
pubmed: 26043024
Cancer Res. 2009 Feb 15;69(4):1545-52
pubmed: 19190324
Theranostics. 2019 Jan 1;9(2):540-553
pubmed: 30809292
Cancers (Basel). 2019 Apr 04;11(4):
pubmed: 30987296
Oncogene. 2018 Jan 18;37(3):363-376
pubmed: 28945225
Blood Cancer J. 2019 Jan 3;9(1):2
pubmed: 30607001
Leukemia. 2014 Nov;28(11):2263-7
pubmed: 25005244
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e324-e336
pubmed: 31076371
Clin Cancer Res. 2018 May 15;24(10):2395-2407
pubmed: 29391353
Leukemia. 2019 Jan;33(1):171-180
pubmed: 30026574
Blood. 2007 Mar 15;109(6):2276-84
pubmed: 17105813
Nat Immunol. 2013 Mar;14(3):298-305
pubmed: 23354484
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Cell Cycle. 2010 Sep 1;9(17):3470-8
pubmed: 20703092
Am J Hematol. 2020 Jun;95(6):672-690
pubmed: 32086970
Blood. 2015 Jan 15;125(3):483-91
pubmed: 25395420
Nature. 2011 Mar 24;471(7339):467-72
pubmed: 21430775
Blood. 2005 Jul 1;106(1):296-303
pubmed: 15755896
Ageing Res Rev. 2015 Sep;23(Pt A):12-28
pubmed: 25555679
Leuk Res. 2013 Aug;37(8):963-9
pubmed: 23537707
Redox Biol. 2015;4:23-33
pubmed: 25485927
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13162-13167
pubmed: 27799547
Leukemia. 2018 Dec;32(12):2604-2616
pubmed: 29789651
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Cancers (Basel). 2019 Mar 28;11(4):
pubmed: 30925767
Leukemia. 2019 Apr;33(4):863-883
pubmed: 30683909
Cancer Lett. 2013 Oct 1;339(1):49-59
pubmed: 23887058
Biochim Biophys Acta. 2013 Dec;1833(12):3460-3470
pubmed: 23850759
Oncotarget. 2017 Dec 1;8(70):114698-114709
pubmed: 29383113
J Hematol Oncol. 2018 Dec 13;11(1):137
pubmed: 30545397
Cell. 2008 Jan 11;132(1):24-6
pubmed: 18191217
Cell Biochem Funct. 2005 Jan-Feb;23(1):47-50
pubmed: 15386538
Oncotarget. 2017 Dec 17;9(1):178-191
pubmed: 29416605
Cancer Res. 2012 Oct 15;72(20):5396-406
pubmed: 22915762
Cancer J. 2019 Jan/Feb;25(1):11-18
pubmed: 30694855
Leukemia. 2015 Feb;29(2):510-4
pubmed: 25306900
Blood. 2011 Jan 27;117(4):1311-4
pubmed: 21081713
EMBO J. 2010 Mar 3;29(5):969-80
pubmed: 20075865
Oncotarget. 2017 Feb 28;8(9):14604-14619
pubmed: 28099937
Mol Cell. 2018 Jan 18;69(2):169-181
pubmed: 29107536
Inflamm Res. 2012 Oct;61(10):1063-7
pubmed: 22674324
PLoS One. 2011;6(10):e25820
pubmed: 22028791
Cancer Discov. 2015 Sep;5(9):972-87
pubmed: 26080835
Cells. 2019 Nov 13;8(11):
pubmed: 31766279